Anacor Pharma (ANAC) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
High Conviction in Anacor Pharmaceuticals (ANAC) Takeout - Mizuho
May 11, 2016 10:31 AM EDTMizuho Securities analyst Irina R. Koffler raised her price target on Buy-rated Anacor Pharmaceuticals (NASDAQ: ANAC) to $98.00 (from $95.00) on takeout potential.
Koffler commented, "We continue to have conviction in an ANAC takeout following the AGN call. The company's 1Q:16 miss should be overlooked in favor... More
